During the last session, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s traded shares were 0.31 million, with the beta value of the company hitting 3.38. At the end of the trading day, the stock’s price was $11.58, reflecting an intraday loss of -3.50% or -$0.42. The 52-week high for the ARCT share is $45.00, that puts it down -288.6 from that peak though still a striking -0.17% loss since the share price plummeted to a 52-week low of $11.60. The company’s market capitalization is $314.05M, and the average intraday trading volume over the past 10 days was 0.34 million shares, and the average trade volume was 407.51K shares over the past three months.
Arcturus Therapeutics Holdings Inc (ARCT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ARCT has a Sell rating from 1 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.0.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) trade information
Arcturus Therapeutics Holdings Inc (ARCT) registered a -3.50% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.50% in intraday trading to $11.58, hitting a weekly high. The stock’s 5-day price performance is -10.09%, and it has moved by -27.90% in 30 days. Based on these gigs, the overall price performance for the year is -63.96%. The short interest in Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is 4.41 million shares and it means that shorts have 9.61 day(s) to cover.
The consensus price target of analysts on Wall Street is $29.29, which implies an increase of 60.46% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10.58 and $48 respectively. As a result, ARCT is trading at a discount of -314.51% off the target high and 8.64% off the low.
Arcturus Therapeutics Holdings Inc (ARCT) estimates and forecasts
In the rating firms’ projections, revenue will decrease -32.94% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 25.64M as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 20.09M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 38.01M and 49.86M respectively. In this case, analysts expect current quarter sales to shrink by -32.54% and then drop by -59.71% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -6.84%. While earnings are projected to return -64.73% in 2025, the next five years will return 48.92% per annum.
ARCT Dividends
Arcturus Therapeutics Holdings Inc is due to release its next quarterly earnings on 2025-Mar-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s Major holders
Arcturus Therapeutics Holdings Inc insiders own 8.45% of total outstanding shares while institutional holders control 92.53%, with the float percentage being 101.07%. FEDERATED HERMES, INC. is the largest shareholder of the company, while 223.0 institutions own stock in it. As of 2024-06-30, the company held over 4.69 million shares (or 17.4067% of all shares), a total value of $114.3 million in shares.
The next largest institutional holding, with 2.65 million shares, is of BLACKROCK INC.’s that is approximately 9.8262% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64.52 million.
Also, the Mutual Funds coming in first place with the largest holdings of Arcturus Therapeutics Holdings Inc (ARCT) shares are Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund and Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund . Data provided on Oct 31, 2024 indicates that Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund owns about 2.44 shares. This amounts to just over 8.98 percent of the company’s overall shares, with a $28.21 million market value. The same data shows that the other fund manager holds slightly less at 2.2, or about 8.10% of the stock, which is worth about $25.45 million.
